Erratum: Efficient identification and referral of low-income women at high risk for hereditary breast cancer: A practice-based approach' [Public Health Genomics 2012;15:172-180, DOI: 10.1159/000336419];Efficient identification and referral of low-income women at high risk for hereditary breast cancer: A practice-based approach

Public Health Genomics

Volumn 15, Issue 3-4, 2012, Pages 172-180

  Joseph, G ^a,c   Kaplan, C ^b   Luce, J ^b   Lee, R ^a   Stewart, S ^d   Guerra, C ^c   Pasick, R ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRCA; Disparities; Hereditary breast and ovarian cancer; Low income; Practice based research

Indexed keywords

ADULT; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENETIC COUNSELING; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; LOWEST INCOME GROUP; PATIENT COUNSELING; PATIENT IDENTIFICATION; PATIENT REFERRAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCREENING TEST;

EID: 84859579301     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000366178     Document Type: Erratum

References (41)

1. Mock J, McPhee SJ, Nguyen T, Wong C, Doan H, Lai KQ, Nguyen KH, Nguyen TT, Bui-Tong N: Effective lay health worker outreach and media-based education for promoting cervical cancer screening among Vietnamese American women. Am J Public Health 2007;97:1693-1700. (Pubitemid 351182336)
2. Robinson CM, Beach ML, Greene MA, Cassells A, Tobin JN, Dietrich AJ: Staffing time required to increase cancer-screening rates through telephone support. J Ambul Care Menage 2010;33:143-154.
3. Vernon SW, McQueen A, Tiro JA, del Junco DJ: Interventions to promote repeat breast cancer screening with mammography: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102:1023-1039.
4. Baron RC, Rimer BK, Breslow RA, Coates RJ, Kerner J, Melillo S, Habarta N, Kalra GP, Chattopadhyay S, Wilson KM, Lee NC, Mullen PD, Coughlin SS, Briss PA; Task Force on Community Preventive Services: Client-directed interventions to increase community demand for breast, cervical, and colorectal cancer screening a systematic review. Am J Prev Med 2008;35(suppl 1):S34-55. (Pubitemid 351787500)
5. American Society of Clinical Oncology: American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21: 2397-2406.
6. National Comprehensive Cancer Network: Genetic/Familial High-Risk Assessment: Breast and Ovarian V.1. Fort Washington, 2008.
7. US Preventive Services Task Force: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143:355-361.
8. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 . Science 2003;302: 6436-6440.
9. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds): SEER Cancer Statistics Review, 1975-2007. Bethesda, National Cancer Institute, 2010.
10. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van't Veer L, Lynch HT, Olopade OI, Weber BL, Rebbeck TR: Mortality after bilateral salpingo- oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223-229. (Pubitemid 43286452)
11. Prat J, Ribé A, Gallardo A: Hereditary ovarian cancer. Hum Pathol 2005;36:861-870. (Pubitemid 41187904)
12. American Cancer Society: Leading Sites of New Cancer Cases and Deaths - 2008 estimates. Cancer Facts and Figures 2008.
13. Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the US Preventive Services Task Force. Ann Intern Med 2005;143:362-379.
14. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117- 1130.
15. Guillem JG, Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, Gagel RF, Weitzel J, Morrow M, Weber BL, Giardiello F, Rodriguez- Bigas MA, Church J, Gruber S, Offit K; ASCO; SSO: ASCO/SSO review of current role of risk-reducing surgery in common hereditary syndromes. J Clin Onc 2006;24:28.
16. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-975.
17. Rodriquez E, Domchek SM: The prevention of hereditary breast cancer. Semin Oncol 2007;34:401-405. (Pubitemid 47503274)
18. Morgan D, Sylvester H, Lucas FL, Miesfeldt S: Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer 2009; 8:277-287.
19. Sivell S, Iredale R, Gray J, Coles B: Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database Syst Rev 2007;2:CD003721.
20. Meiser B, Eisenbruch M, Barlow-Stewart K, Tucker K, Steel Z, Goldstein D: Cultural aspects of cancer genetics: setting a research agenda. J Med Genet 2001;38:425-429. (Pubitemid 32661202)
21. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, Wenstrup RJ, Ward BE, Scholl TA, Noll WW: BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breastovarian cancer. Cancer 2009;115:2222- 2233.
22. Whittemore AS, Gong G, Itnyre J: Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504. (Pubitemid 27097597)
23. John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, West DW, Whittemore AS: Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007;298:2869-2876.
24. US Census Bureau, Income Poverty and Health Insurance Coverage in the US: 2008, Current Population Reports. Series P60-236 and historical tables - tables 2 and 6, 2009.
25. Halbert CH, Kessler LJ, Mitchell E: Genetic testing for inherited breast cancer risk in African Americans. Cancer Invest 2005;23:285-295. (Pubitemid 41656967)
26. Schaefer GB, Dunston GM: Health-care disparities in medical genetics; in Satcher D, Paimes RJ (eds): Multicultural Medicine and Health Disparities. New York, McGraw-Hill, 2006, pp 471-484.
27. Antoniou AC, Pharoah PP, Smith P, Easton DF: The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004;91:1580-1590. (Pubitemid 39486366)
28. Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F: A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004;41:474-480. (Pubitemid 38788046)
29. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002;20:2701-2712. (Pubitemid 34575644)
30. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2 : analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490. (Pubitemid 34260526)
31. Lindor NM, Johnson KJ, Harvey H, Shane Pankratz V, Domchek SM, Hunt K, Wilson M, Cathie Smith M, Couch F: Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Fam Cancer 2010;9:495-502.
32. Green LW, Glasgow R: Evaluating the relevance, generalization, and applicability of research: issues in external validity and translation methodology. Eval Health Prof 2006;29:126-153. (Pubitemid 43797500)
33. Green LW: Making research relevant: if it is an evidence based practice, where's the practice- based evidence? Fam Pract 2008;25(suppl 1):i20-i24.
34. Glasgow RE: What types of evidence are most needed to advance behavioral medicine? Ann Behav Med 2008;35:19-25.
35. Joseph G, Kaplan CP, Pasick RJ: Recruiting healthy low-income women to research: an exploratory study. Ethn Health 2007;12:497-519. (Pubitemid 350058913)
36. Joseph G, Nguyen T, Nguyen K, Stewart S, Pasick R: Efficient Identification of Low-Income Asian American Women at Risk for Hepatitis B, in preparation.
37. Hoskins KF, Zwaagstra A, Ranz M: Validation of a tool for identifying women at high risk for hereditary breast cancer in population- based screening. Cancer 2006;107: 1769-1776. (Pubitemid 44582945)
38. Teller P, Hoskins KF, Zwaagstra A, Stanislaw C, Iyengar R, Green VL, Gabram SG: Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations. Ann Surg Oncol 2009;17:240-246.
39. Gilpin CA, Carson N, Hunter AG: A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 2000;58:299-308.
40. Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT: Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med 2009;11:783-789.
41. Bellcross C: Further development and evaluation of a breast/ovarian cancer genetics referral screening tool. Genet Med 2010;12:240.